Allakos Inc (ALLK)

Precedente Chiudi:

$1.05

Aprire:

$1.06

Volume 24 ore:

424.44K

Capitalizzazione di mercato:

$100.06M

Reddito:

-

Utile/perdita netta:

$-166.14M

Rapporto P/E:

-0.5855

EPS:

-1.93

Flusso di cassa netto:

$-139.92M

1 W Prestazione:

+10.78%

1M Prestazione:

-7.38%

6M Prestazione:

-40.53%

1 anno Prestazione:

-74.55%

Intervallo 1D:

$1.06

$1.18

Portata 52W:

$0.9799

$5.64

Allakos Inc Stock (ALLK) Company Profile

Nome

Allakos Inc

Settore

Healthcare (1189)

Industria

Biotechnology (685)

Telefono

650-597-5002

Indirizzo

75 Shoreway Road, Suite A, San Carlos, CA

Dipendente

51

Cinguettio

Prossima data di guadagno

2024-05-24

Ultimi documenti SEC

ALLK's Discussions on Twitter

Allakos Inc Stock (ALLK) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-05-12	Aggiornamento	Jefferies	Hold → Buy
2023-03-07	Iniziato	Piper Sandler	Overweight
2022-09-12	Downgrade	SMBC Nikko	Neutral → Underperform
2021-12-22	Downgrade	BofA Securities	Buy → Underperform
2021-12-22	Downgrade	Cowen	Outperform → Market Perform
2021-12-22	Downgrade	Jefferies	Buy → Hold
2021-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
2021-12-22	Downgrade	William Blair	Outperform → Mkt Perform
2021-08-26	Iniziato	Morgan Stanley	Equal-Weight
2021-07-15	Iniziato	Cowen	Outperform
2021-05-18	Iniziato	H.C. Wainwright	Buy
2021-02-24	Iniziato	Cantor Fitzgerald	Overweight
2021-01-15	Iniziato	BofA Securities	Buy
2020-12-21	Iniziato	SVB Leerink	Outperform
2020-02-27	Iniziato	Barclays	Underweight
2020-02-04	Ripresa	Goldman	Neutral
2018-08-13	Iniziato	Goldman	Neutral
2018-08-13	Iniziato	Jefferies	Buy
2018-08-13	Iniziato	William Blair	Outperform

Mostra tutto

Allakos Inc Borsa (ALLK) Ultime notizie

Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions

Zacks Investment Research

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire Inc.

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

GlobeNewswire Inc.

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

GlobeNewswire Inc.

Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update

Zacks Investment Research

Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug

Zacks Investment Research

Allakos Inc Azioni (ALLK) Dati Finanziari

Allakos Inc (ALLK) Reddito netto 2024

Allakos Inc (ALLK) Flusso di cassa 2024

Allakos Inc (ALLK) Utile per azione 2024